We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > aTTP

News List

NICE green light for Cablivi in rare blood-clotting disorder pharmatimes
November 16, 2020
The UK’s National Institute for Health and Care Excellence (NICE) has given a green light to Sanofi’s Cablivi for acquired thrombotic thrombocytopenic purpura (aTTP) – a rare and potentially life-threatening blood clotting disorder.
Top novel drug approvals: February 2019 europeanpharmaceuticalreview
April 12, 2019
Cablivi and Egaten were the two top novel drugs approved last month, with a focus on parasitic infestation and the rare disorder, aTTP…
FDA grants fast-track status for Ablynx’s caplacizumab to treat aTTP pharmaceutical-technology
July 31, 2017
Belgian biopharmaceutical company Ablynx has received fast-track designation from the US Food and Drug Administration (FDA) for its caplacizumab treatment for acquired thrombotic thrombocytopenic purpura (aTTP).